Hcw Biologics Inc (HCWB)

$4.35 -0.07 (-1.58%)
Market Cap 6.26M
Revenue (ttm) 2.57M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,168.09%
Debt to Equity Ratio -1.63
Volume 37,200
Avg Vol 919,280
Day's Range N/A - N/A
Shares Out 1.44M
Stochastic %K 77%
Beta 0.65
Analysts Strong Sell
Price Target $35.00

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is i...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 842 2024
Fax: 954 842 2037
Address:
2929 North Commerce Parkway, Miramar, United States
Jenileesa
Jenileesa Jul. 10 at 7:18 PM
$HCWB bought since July 1 at $4 avg. Now $4.48.. 👀
0 · Reply
novicetrader23
novicetrader23 Jul. 10 at 6:50 PM
$HCWB priming up for a run?
0 · Reply
StockMan51
StockMan51 Jul. 9 at 2:19 PM
$HCWB
1 · Reply
oppdealer1982
oppdealer1982 Jul. 8 at 12:11 AM
$HCWB ; premarket opening at $17 .
2 · Reply
AZOZ
AZOZ Jul. 7 at 1:27 PM
$HCWB are you ready 😎
0 · Reply
StockMan51
StockMan51 Jul. 7 at 9:19 AM
$HCWB what's going on with this ticker. any upcoming?
0 · Reply
kdnapedIPOmidweek
kdnapedIPOmidweek Jul. 7 at 12:08 AM
$HCWB As soon as partnership with wy tech is confirmed
1 · Reply
SWEEN24
SWEEN24 Jul. 6 at 1:40 PM
$HCWB we going up from here or dropping to low 2's? Hopefully up.
0 · Reply
RollingDollars
RollingDollars Jul. 3 at 1:47 PM
$HCWB
0 · Reply
RollingDollars
RollingDollars Jul. 3 at 1:01 PM
$HCWB
0 · Reply
Latest News on HCWB
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 27, 2025, 7:45 AM EDT - 17 days ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 26, 2025, 7:55 AM EDT - 18 days ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

Jun 4, 2025, 8:20 AM EDT - 5 weeks ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 6:14 PM EDT - 2 months ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:01 PM EDT - 2 months ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:30 AM EDT - 2 months ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Announces 1-for-40 Reverse Stock Split

Apr 1, 2025, 4:35 PM EDT - 3 months ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 3:30 PM EDT - 3 months ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Mar 6, 2025, 6:55 AM EST - 4 months ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Feb 3, 2025, 7:15 AM EST - 5 months ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Jan 15, 2025, 7:00 AM EST - 6 months ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Dec 23, 2024, 8:10 AM EST - 7 months ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 9:27 PM EST - 8 months ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Why Is Penny Stock HCW Biologics Surging On Monday?

Nov 18, 2024, 10:15 AM EST - 8 months ago

Why Is Penny Stock HCW Biologics Surging On Monday?

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 18, 2024, 7:00 AM EST - 8 months ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 4:40 PM EST - 8 months ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 23, 2024, 4:30 PM EDT - 11 months ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 4:35 PM EDT - 11 months ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Apr 1, 2024, 4:10 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 1 year ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 8, 2023, 7:30 AM EST - 1 year ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 1 year ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Sep 6, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Jun 14, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

May 9, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Apr 27, 2023, 7:40 AM EDT - 2 years ago

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Apr 13, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Apr 3, 2023, 8:13 AM EDT - 2 years ago

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 4:25 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

HCW Biologics Enters CRADA with National Cancer Institute

Dec 8, 2022, 7:55 AM EST - 2 years ago

HCW Biologics Enters CRADA with National Cancer Institute

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Dec 7, 2022, 7:30 AM EST - 2 years ago

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Nov 8, 2022, 7:00 AM EST - 2 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

Nov 7, 2022, 4:45 PM EST - 2 years ago

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

Aug 31, 2022, 9:22 AM EDT - 3 years ago

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

SMSI

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

CASI HSDT

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

Aug 12, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

Aug 3, 2022, 7:15 AM EDT - 3 years ago

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

May 23, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 13, 2022, 7:15 AM EDT - 3 years ago

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

May 5, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

HCW Biologics' CEO Hing C. Wong, Ph.D.

Apr 19, 2022, 7:33 AM EDT - 3 years ago

HCW Biologics' CEO Hing C. Wong, Ph.D.

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

Mar 28, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

Mar 24, 2022, 8:00 AM EDT - 3 years ago

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

Jan 24, 2022, 9:22 AM EST - 3 years ago

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein

Jan 24, 2022, 7:00 AM EST - 3 years ago

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

Jan 20, 2022, 9:24 AM EST - 3 years ago

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

Jan 20, 2022, 8:00 AM EST - 3 years ago

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022

Jan 19, 2022, 8:00 AM EST - 3 years ago

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022

Jenileesa
Jenileesa Jul. 10 at 7:18 PM
$HCWB bought since July 1 at $4 avg. Now $4.48.. 👀
0 · Reply
novicetrader23
novicetrader23 Jul. 10 at 6:50 PM
$HCWB priming up for a run?
0 · Reply
StockMan51
StockMan51 Jul. 9 at 2:19 PM
$HCWB
1 · Reply
oppdealer1982
oppdealer1982 Jul. 8 at 12:11 AM
$HCWB ; premarket opening at $17 .
2 · Reply
AZOZ
AZOZ Jul. 7 at 1:27 PM
$HCWB are you ready 😎
0 · Reply
StockMan51
StockMan51 Jul. 7 at 9:19 AM
$HCWB what's going on with this ticker. any upcoming?
0 · Reply
kdnapedIPOmidweek
kdnapedIPOmidweek Jul. 7 at 12:08 AM
$HCWB As soon as partnership with wy tech is confirmed
1 · Reply
SWEEN24
SWEEN24 Jul. 6 at 1:40 PM
$HCWB we going up from here or dropping to low 2's? Hopefully up.
0 · Reply
RollingDollars
RollingDollars Jul. 3 at 1:47 PM
$HCWB
0 · Reply
RollingDollars
RollingDollars Jul. 3 at 1:01 PM
$HCWB
0 · Reply
simplifocused
simplifocused Jul. 2 at 7:33 PM
$HCWB Thanks for alerting this AZOZ. What is your view on $BMNR NFA
0 · Reply
Mercuria
Mercuria Jul. 2 at 6:39 PM
$HCWB Come on in… waters warm!
0 · Reply
RollingDollars
RollingDollars Jul. 2 at 6:12 PM
$HCWB
0 · Reply
AZOZ
AZOZ Jul. 2 at 3:39 PM
$HCWB tiny floater worth to keep close eye on it folks before the crowd!
0 · Reply
oppdealer1982
oppdealer1982 Jul. 1 at 8:18 PM
$HCWB ; Soon premarket opening at $17 !!!
0 · Reply
stockWare
stockWare Jun. 30 at 9:57 PM
$APDN could be another bear trap $HCWB $WBUY
1 · Reply
Snichols1988
Snichols1988 Jun. 27 at 7:12 PM
$HCWB anyone else headed gere for ah?
1 · Reply
Sonnyman4
Sonnyman4 Jun. 27 at 4:00 PM
$HCWB keeping a eye on AH
0 · Reply
Trader1141
Trader1141 Jun. 27 at 3:26 PM
$GVH $INMB $HCWB It’s a bear market short, living it up 😎
0 · Reply
MarketMasterMind
MarketMasterMind Jun. 27 at 3:26 PM
$HCWB loaded 🤑Ⓜ️
0 · Reply
frankyboyz
frankyboyz Jun. 27 at 2:41 PM
$HCWB 4.20-5.47 ciao $HCWB
0 · Reply
bubsomatic
bubsomatic Jun. 27 at 2:40 PM
$HCWB about time
0 · Reply